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Abstract
Toll-like receptors (TLRs) recognize specific motifs 
which are frequently present in bacteria, fungi, pro-
karyotes and viruses. Amongst TLRs, TLR9 can be 
activated by such bacterial or viral DNA fragments, 
immunoglobulin-DNA complexes or synthetic oligo-
nucleotides, which all contain unmethylated cytosine-
guanine nucleotide sequences (CpGs). Emerging data 
indicate that TLR9 signaling has a role in, and may 
influence, colorectal carcinogenesis and colonic inflam-
mation. CpGs are classified into three groups according 
to their influence on both the antigen-specific humoral- 
and cellular immunity, and the production of type 1 
interferons and proinflammatory cytokines. TLR9 acti-
vation via  CpGs may serve as a new therapeutic target 
for several cancerous and various inflammatory condi-
tions. Due to its probable anti-cancer effects, the ap-
plication possibilities of TLR9-signaling modulation may 
be extremely diverse even in colorectal tumors. In this 
review we aimed to summarize the current knowledge 
about TLR-signaling in the pathogenesis and therapy of 
inflammatory bowel diseases and colorectal cancer. Due 
to the species-specific differences in TLR9 expression, 
however, one must be careful in translating the animal 
model data into the human system, because of the dif-
ferences between CpG-oligodeoxynucleotide-responsive 
cells. TLR9 agonist DNA-based immunomodulatory se-
quences could also represent a promising therapeutic 
alternative in systemic inflammatory conditions and 
chronic colonic inflammations as their side effects are 
not significant. 
© 2013 Baishideng. All rights reserved.
Key words: Toll-like receptor 9; Synthetic oligodeoxy-
nucleotide sequences; DNA-based immunomodulatory 
sequences; Colorectal cancer; Inflammatory bowel dis-
eases
Core tip: Toll-like receptor 9 mediated signaling influ-
ences and regulates the severity of mucosal inflam-
mation, and seems to have a protective role against 
malignant transformation. The modulation of toll-like 
receptor 9 signaling by synthetic oligodeoxynucleotide 
agonists or antagonists seems to have beneficial thera-
peutic effect in inflammatory and cancerous colonic 
disorders. 
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INTRODUCTION
The immunostimulatory effect of  DNA was discovered 
by William Coley, a surgeon from New York[1]. He used 
living and heat-treated bacteria as a therapeutic option for 
different kinds of  tumors. It has long been known that 
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microbes contain many immunostimulatory ingredients. 
In 1980, Tokunaga et al[2] identified the bacterial DNA 
as a main ingredient of  the Coley-lysate. Later, they also 
showed that the same immunostimulatory effect could be 
achieved by using short synthetic oligodeoxynucleotide 
sequences (ODNs)[3,4]. In 2000, it was proven that DNA 
sequences are mainly recognized by the members of  the 
Toll-like receptor (TLR) superfamily[5]. It has also been 
proven that in TLR9 knock out mice, microbial DNA 
fragments cannot result in an immune response[5]. It was 
also shown that the immunomodulating effect of  natural 
and synthetic ODNs is mainly transmitted by TLR9[6]. 
Peyer’s patches (PPs) and isolated lymphoid follicles 
(ILFs) are immunologic and regenerative organizers of  
the gut mucosa, and they also represent a unique switch 
point between colonic inflammation and cancer[7]. Mi-
crofold (M) cells are located in the follicle associated 
epithelium (FAE) of  PPs and ILFs, where they medi-
ate the uptake and transcytosis of  luminal antigens to 
the underlying lymphoid tissue. TLR9 was found to be 
preferentially expressed in M cells[8]. Some TLR polymor-
phisms are known to be associated with the susceptibility 
of  inflammatory bowel diseases (IBD)[9-11] and sporadic 
colorectal cancer (CRC) development[12,13], but the current 
and concrete pathogenic role of  TLRs, including TLR9, 
remains uncertain in these conditions. 
In this review we aimed to summarize the current 
knowledge about TLR-signaling in the pathogenesis of  
IBD and CRC, focusing especially on TLR9. Recent data 
indicate that targeting TLR9-signaling may yield new and 
promising therapeutic approaches to these conditions. 
LIGANDS AND SIGNALING OF TOLL-LIKE 
RECEPTORS
TLRs belong to the type 1 transmembrane glycopro-
teins, which contain extracellular leucin-reach repeated 
sequences and Toll/interleukin-1 receptor signaling do-
mains. TLR4 was the first to be identified, and currently 
10 TLRs have been identified in humans, while 13 have 
been identified in mice[14]. TLRs are mainly expressed in 
the cells of  the innate and adaptive immunity (i.e., mono-
cytes, macrophages, lymphocytes, mast cells, dendritic 
cells), however, some (TLR4, -5 and -9) may be expressed 
by modified epithelial cells as well[15]. Apical epithelial 
TLR9 activation by bacterial DNA fragments has been 
reported to maintain colonic homeostasis[16].
TLRs usually recognize microbial wall components, 
DNA and ribonucleic acid (RNA) fragments. TLR1, -2, 
-4, -5, and -6 are localized to the cell surface, while TLR3, 
-7, -8, and -9 are present in the intracellular compart-
ment[17-20]. TLRs bind specific motifs, which frequently 
appear in bacteria, fungi, protozoa, and viruses[21,22]. 
These motifs can be lipids and lipopeptides (TLR1, -2, -4, 
-6), bacterial flagelline (TLR5), and fragments of  nucleic 
acids (TLR3, - 7, -8, -9). TLR3 binds double stranded 
RNA from viruses, while TLR7 and -8 can recognize 
single stranded RNAs. Moreover, TLR7 recognizes 
immunoglobuline-self-RNA complexes in autoimmune 
disease conditions. Imiquimod is a specific ligand for 
TLR7. TLR9 could be activated by bacterial and viral 
DNA, immunoglobuline-DNA complexes, and synthetic 
ODNs, which contain unmethylated CpG sequences[21,22].
The signals transmitted by TLRs activate both innate 
and adaptive immunity. Due to the immune evasion na-
ture of  tumor cells, the dysregulated activation of  adap-
tive and innate immune systems could result in cytotoxic 
effects. This could in turn eradicate the diseased cells or 
even control the tumorous progression. TLRs recognize 
pathogen-associated molecular patterns (PAMPs) origi-
nating from microbiota and could also bind endogenous 
ligands, such as danger-associated molecular patterns 
(DAMPs)[23]. Both bacterial DNA and synthetic ODNs 
activate the innate and adaptive immune system via plas-
macytoid dendritic cells (pDCs) and macrophages[24]. 
TOLL-LIKE RECEPTOR 9 SIGNALING
Due to TLR9-associated activation, pDCs produce 
interferon-α which influences the cytokine production 
of  B cells[24] resulting in pro- (e.g., interleukin 6, tumor-
necrosis factor-α) and anti-inflammatory (e.g., interleukin 
10) cytokine release and co-expression of  MHC Ⅱ type 
surface antigens. 
The activation of  TLR9 is a complex pathway. The 
uptake of  DNA sequences is the most unclear process, 
which is influenced by the structure of  the DNA frag-
ments. Many cell types can easily take up single stranded 
DNA, but the uptake of  double stranded DNA may be 
more effective if  a cationic lipid is used for packing it in, 
because TLR9 is located in the intracellular compartment 
of  endosomes[24,25]. It was shown that fluorescein isothio-
cyanate labelled CpG DNA is transferred to the intracel-
lular compartment by non-specific endocytosis[25]. This 
transport is non-specific, because DNA sequences lack-
ing CpG dinucleotides may also be recognized by TLR9, 
and this way of  immune activation can be competitively 
inhibited by non-CpG sequences[25]. After transporta-
tion to the intracellular compartment, endosomal acidic 
maturation occurs. This process may be inhibited by pH 
raising agents (e.g., chloroquine, bafilomycin A)[25]. Finally 
pro- and anti-inflammatory cytokines may be released 
and B cell proliferation may be enhanced[25]. The main 
steps of  TLR9-signaling are summarized in Figure 1. 
The signal molecules of  this pathway [e.g., myeloid 
differentiation primary response gene 88 (Myd88), tumor 
necrosis factor receptor-associated factor 6 (TRAF6), 
interleukin receptor associated kinase (IRAK)-1, -4; p50/
p65 heterodimer of  nuclear factor (NF)-κB] are non- 
specific and are also involved in the signaling of  other 
TLRs. Interferons may also be released by a mitogen acti-
vated protein kinase (MAPK)-associated pathway, which 
is also intensively being investigated[26]. 
CPG OLIGODEOXYNUCLEOTIDE 
CLASSES
The immunostimulatory effect of  unmethylated CpG 
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sequences has been proven in mice and in other species, 
as well as in in vitro human cell line experiments[27,28]. The 
CpG DNA sequences can be classified into three classes 
based on the different immune cell-mediated immune 
responses and their chemical structure. It has already 
been documented how these differences in the chemi-
cal structure may determine the immunostimulatory ef-
fect of  these sequences on immune cells[29]. Liu et al[29] 
demonstrated in mice that three CpG-ODN classes can 
differentially affect antigen-specific humoral and cellular 
immune responses. Specifically, the B- and C-class CpG-
ODNs induced a potent Th1-mediated immunity with 
comparable antibody levels as well as CD4+ and CD8+ 
T cell responses. In contrast, although the A-class CpG-
ODNs weakly enhanced antibody titers and CD8+ T 
cell response regarding cytotoxic activity, they were not 
able to change the IgG1/IgG2a ratio or elicit antigen-
specific, interferon γ-secreting CD4+ and CD8+ T cells. 
Consistent with this, three CpG-ODN classes provided 
differential antigen-specific protection against an intra-
cellular bacterial infection (i.e., Listeria monocytogenes). 
These three classes of  CpG-ODNs did not show signifi-
cant differences regarding the interleukin 12 producing 
effect[30,31]. These results may provide not only better 
understanding of  the adjuvant activities of  three CpG-
ODN classes, but also of  implications for the rational 
design of  CpG-ODN adjuvants.
CONTRIBUTION OF TOLL-LIKE RECEPTOR 
9 POLYMORPHISM TO DISEASE 
DEVELOPMENT
Components of  Gram-negative bacterial cell walls alert 
the host to invading bacteria and activate innate immu-
nity. These responses are usually effective in combating 
infection and restoring normal host function. However, 
in individuals susceptible to IBD, they may become ex-
cessive and lead to mucosal damage.
In genes for all the contributing proteins, single 
nucleotide polymorphisms (SNPs) have been identified 
that may increase IBD susceptibility[32]. There are several 
lines of  sensing bacterial components (described earlier), 
all of  which result in activation of  NF-κB, and thereby 
stimulate the innate immune response. In genes of  TLR9 
signaling, SNPs have been found that may increase IBD 
susceptibility[9,33]. Török et al[9] reported that a SNP in the 
promoter region of  the TLR9 gene was associated with 
increased risk of  Crohn’s disease in a German cohort. 
These genetic findings confirm an important role for 
innate immunity, pro- and anti-inflammatory immune 
responses for both gut homeostasis and the development 
of  chronic inflammation in IBD.
Regarding the connection between polymorphisms in 
TLR9 genes and the risk of  colorectal cancer no data are 
currently available.
ROLE OF TOLL-LIKE RECEPTOR 9 
SIGNALING IN COLONIC INFLAMMATION 
AND CARCINOGENESIS
The commensal microbiota of  the intestinal tract confer 
multiple health benefits to the host, including ameliora-
tion of  IBD. It was recently identified that TLR9-induced 
type 1 interferons mediate the anti-inflammatory effects 
in experimental colitis[34]. The addition of  neutralization 
antibodies to type 1 interferons abolished the anti-inflam-
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Figure 1  Toll-like receptors 9-mediated cytokine release in the colonic mucosa. Binding DNA fragments by toll-like receptors (TLRs) of plasmacytoid dendritic 
cells (pDCs) results in pro-inflammatory cytokine release and subsequent B cell activation together with both CD80 overexpression and B cell proliferation. CD80 pro-
vides a costimulatory signal necessary for T cell activation and survival. IFN: Interferon; TNF: Tumor necrosis factor; IL: Interleukin. 
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free 5’ end. The CpG DNA sequence had dimer struc-
ture, where the 3-3’ ends were connected by glycerin or 
2’-deoxy-7-deazaguanosine modification. Mutation of  
the K-ras gene has a critical role in colon, lung and pan-
creatic cancers, and may cause a resistance to anti-EGFR 
therapy[40,41]. This is the reason why panitumumab and 
cetuximab therapy do not show a positive effect on the 
control of  proliferation and metastasis of  K-ras mutated 
colon cancer. This kind of  biologic therapy could be only 
useful in the case of  patients carrying the wild type K-ras 
gene[40]. 
It was shown in an in vivo murine xenograft model 
and in vitro human cancer cell lines (GEO, SW48 and 
LS174T) that IMOs can restore the therapy sensitivity for 
K-ras mutant colon and pancreatic cancers[40]. These cell 
lines, except GEO, were resistant for EGFR inhibition 
therapy, if  they had a K-ras mutation. A small number of  
GEO cells carrying K-ras mutations showed sensitivity 
to anti-EGFR antibodies. This demonstrates that cells 
could carry a different K-ras mutation and could respond 
to EGFR inhibition therapy in a different way based on 
their K-ras status[39-41]. 
TLR9 agonists were also tested on a breast cancer cell 
line which was estrogen receptor positive[42]. After estro-
gen-TLR9 agonist combination the test showed signifi-
cant reduction of  transactivation via the estrogen recep-
tor. Estrogen receptors may also take part in colorectal 
carcinogenesis[43,44], therefore, this interaction may have 
further therapeutic importance in colorectal cancer as 
well. 
Currently, TLR9 agonist therapy has been tested clini-
cally on colon, pancreatic and breast cancers[45-48], and 
experiments are running on oesophageal squamous cell 
cancer[49], melanomas[50], lymphomas[51,52], non-small cell 
lung carcinomas[53], renal tumors[47] and androgen resis-
tant prostate cancers[54].
Toll-like receptor agonists in inflammatory bowel 
disease
It has long been known that in IBD patients, antibod-
ies against own or microbial antigens can be detected. 
Antibodies against Saccharomyces cerevisiae, outer mem-
brane porin, Pseudomonas fluorescens, pancreas, bacte-
rial flagelline as well as anti-chitobioside-, anti-laminaribi-
oside-, and anti-mannobioside antibodies[55] have all been 
identified. These antibodies are recognized by PAMP 
and DAMP receptors. The most important members of  
these receptor families are the nucleotide oligomerization 
domain (NOD) - caspase recruitment domain (CARD) 
system (mainly NOD2 receptor in Crohn’s disease) and 
TLRs. These receptors are localized in the intestinal 
mucosa, and by increased activation and genetic poly-
morphisms these receptors create an excessive immune 
response. At the end of  the pathway pro-inflammatory 
cytokines are released, regulatory T cells are thought to 
loose their control function and the Th1/Th17 cell sub-
population becomes over-expressed[55,56-58].
Rachmilewitz et al[56] used IMOs in a DSS-induced 
matory effects, whereas the administration of  recombi-
nant interferon-β mimicked the anti-inflammatory effects 
induced by TLR9 agonists. 
The relapse of  IBD may occur following an infection 
with Campylobacter jejuni (C. jejuni). In a murine model of  
dextran sulfate sodium (DSS) induced colitis, the infec-
tion of  the animals by C. jejuni disrupted TLR9-induced 
reinforcement of  the intestinal epithelial barrier and 
colonization by C. jejuni increased the severity of  DSS-
induced colitis[35]. 
In humans, the gene expression and protein expres-
sion level of  not just TLR2, -4, and -8, but also TLR9 
increased in the biopsy samples of  active ulcerative colitis 
patients. Furthermore, the levels of  these TLRs positively 
correlated with the severity of  intestinal inflammation as 
well as with inflammatory cytokine production[36]. Based 
on these results, it is plausible that TLR9 mediated signal-
ing influences and regulates the severity of  the mucosal 
inflammation. 
In colonic carcinogenesis the role of  TLR9 signaling 
is not well studied. It was recently published that ODNs 
targeting TLR9 oppositely modulate DNA repair genes in 
tumor versus immune cells and enhance the biologic ef-
fects of  chemotherapy[37]. The first publication about the 
relation of  TLR9 expression to colonic carcinogenesis 
was also published nowadays[38]. Eiró et al[38] found TLR9 
expression to be higher in hyperplastic or adenomatous 
polyps compared to other polyp types. TLR9 expression 
was decreased in hyperplastic and villous polyps from 
patients who developed colorectal cancer. Their findings 
suggest a possible protective role of  TLR9 expression 
against malignant transformation in the colorectal mu-
cosa. 
THERAPEUTIC POTENTIAL OF TOLL-LIKE 
RECEPTOR AGONISTS
The therapeutic targeting of  TLRs may be useful in dis-
eases such as tumors, allergies or viral infections. In these 
disorders, TLR agonists and antagonists result in a differ-
ent immune response. In allergic diseases, like asthma or 
inflammatory conditions, such as IBD, these agents have 
an important effect on T cells. For a wider spectrum of  
anti-tumoral immune response TLR agonists in tumor-
ous diseases require the involvement of  the innate immu-
nity, pDCs, monocytes and macrophages, as well as the 
activation of  Th1-dependent immunity and induction of  
apoptosis[28]. 
Toll-like receptor agonists in colorectal cancer
In 2011, Rosa et al[39] demonstarted that an immuno-
modulatory oligonucleotide sequence (IMO) in combi-
nation with cetuximab has an antitumorous effect on a 
K-ras mutated colorectal carcinoma model. This is prob-
ably based on the alteration of  MAPK phosphorylation 
and results in structural and functional changes in the 
relationship between epidermal growth factor receptor 
(EGFR) and TLR9[39]. They used a synthetic IMO having 
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colitis mouse model and found decreased IL-6, IL-12 
and interferon mRNA levels. The levels of  matrix metal-
loproteinases were found to be proportionally decreased. 
The immunological, clinical, biochemical and histological 
results showed decreased activity index of  the inflam-
mation. From these data one could suggest that the con-
tinuous presence of  bacteria and bacterial DNA, which 
densely contain non-methylated CpG sequences, may act 
as a physiological factor. Furthermore, they could influ-
ence the release of  inflammatory cytokines in IBD and 
thus may serve as a therapeutic tool[57].
A newly developed therapeutic agent is a synthetic 
DNA-based immunomodulatory sequence (DIMS0150), 
which acts through TLR9 signaling[57]. Based on the re-
sults of  clinical trials, DIMS0150 seems to restore the 
steroid sensitivity of  the mucosa in steroid-resistant ul-
cerative colitis patients. In the third phase of  clinical tri-
als, 71% of  patients achieved remission after 12 weeks of  
administration of  this drug[57]. Although it has no notable 
side effects, the mode of  its administration, namely it has 
to be spread over the inflamed mucosa with the help of  
a spray catheter during colonoscopy, makes its use widely 
intolerable for patients. New ways of  drug administration 
(i.e., colon solvent capsules) must be developed in the 
near future. 
Based on the results of  clinical trials[45-54], TLR9 ago-
nists are therapeutically safe in vivo. Only some minor side 
effects, mainly a dose-dependent local inflammation of  
the connective tissue were observed. 
THERAPEUTIC POTENTIAL OF TOLL-LIKE 
RECEPTOR 9 ANTAGONISTS
Due to complex signaling of  oligodeoxynucleotide bind-
ing TLRs (including TLR9) a dynamic regulation of  pro- 
and anti-inflammatory cytokines is present[59]. Therefore, 
TLR9 antagonists and inhibitory oligodeoxynucleotides 
(inh-ODNs) also may represent new therapeutic op-
tions[60] in the treatment of  autoimmune diseases. The 
mechanism of  their action is by controlling and blocking 
the dangerous immune response activated by the self-
antigen recognizing receptors. Interestingly, inh-ODNs 
have TLR9 (and TLR7) antagonist activity, but this effect 
is sequence dependent. These inhibitory oligonucleotides 
competitively inhibit TLR9 activation in a manner that 
competitively antagonizes the binding of  ligands to the 
active, proteolytically cleaved TLR9 sequence. Their ther-
apeutic use shows promise in systemic autoimmune dis-
eases, DNA-mediated sepsis, and chronic inflammatory 
conditions (e.g., IBD) in which TLR9 plays an important 
role[60]. 
SPECIES-SPECIFIC DIFFERENCE IN TOLL-
LIKE RECEPTOR 9 EXPRESSION
In the majority of  in vivo studies mice were used as animal 
models for showing that CpG-ODNs are effective both 
as adjuvants and for therapeutic intervention in infec-
tious and tumour model systems. However, one must 
be careful in translating the murine data into the human 
system, because of  the differences between CpG-ODN-
responsive cells in mice and humans. One major and 
important difference between mice and humans refers to 
the expression pattern of  TLR9. In humans, only pDC 
and B cells express TLR9 and respond directly to TLR9 
activation. All other effects of  TLR9 ligands on human 
immune cells seem to be indirect and depend on factors 
produced by pDCs and B cells[61]. 
The situation in mice is different because not only 
pDCs and B cells, but other dendritic cell subsets and 
macrophages express TLR9 and thus respond directly to 
TLR9 activation[61]. Given this important species-specific 
difference in TLR9 expression, mice are not ideal animal 
models for establishing TLR9-based therapeutic strate-
gies. The natural ligands for TLR9 can be mimicked by 
special CpG-ODNs[62]. 
Besides rodent models, a few studies have analysed 
the immune response of  CpG-ODNs in other animals[62]. 
Guzylack-Piriou et al[63] demonstrated that pig pDCs are 
the main producers of  interferon-α in response to certain 
CpG-ODNs. Importantly, they additionally showed that 
myeloid DCs and monocytes/macrophages are refractory 
to CpG-ODNs. Thus, the CpG-ODN responsiveness in 
pigs seems to mimic the situation in humans, and there-
fore recommends the pig as an animal model for preclini-
cal studies with CpG-ODN.
CONCLUSION
Since the immunomodulatory effects of  TLRs are 
known, they are the center of  biological, immunological 
and therapeutic research. Most of  the research teams are 
dealing with the potential therapeutic use of  TLR9 ago-
nists and antagonists because their use is not restricted to 
a specific group of  patients. They can be widely applied 
in almost all diseases where dysregulated immunity plays 
a central role via antibody production or phagocytosis by 
macrophages. 
TLR9 plays a central role in both innate and adapti-
ve immunity. The signalling cascade mediated by CpG 
ODNs is a complicated pathway and contains many 
steps, including the synthesis of  proinflamatory cytokines 
and the production of  interferons, and thus significant 
activation of  pDCs and T-lymphocytes. The activation 
of  TLR9 acts as a new therapeutic modality in bacterial, 
viral, inflammatory and neoplastic diseases. In inflam-
matory circumstances, TLR9 agonists act by both dec-
reasing the enormous immune activation, especially in 
IBD, and setting the balance of  the Th1/Th2 immune 
response. They may have an effect on the suppressi-
on of  Th1/Th17 overexpression as well. In tumorous 
conditions, especially in colorectal cancer, these agents 
were able to restore anti-EGFR therapy sensitivity cau-
sed by a K-ras mutation. They also seem to be effective 
therapeutic agents in estrogen receptor positive breast 
Fűri I et al . TLR9 in colitis and CRC
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cancers, androgen-resistant prostate tumors, melanomas, 
lymphomas, large cell lung cancers and renal tumors. The 
side effects of  TLR9 agonists are not significant. Further 
investigations of  these new therapeutic modalities may 
have promising results in the near future. 
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